Zealand Pharma (OTCPK:ZLDP.Y) 2025 Earnings Call Presentation

Zealand Pharma's Strategic Vision - Zealand Pharma aims to redefine obesity care and build a generational biotech company in metabolic health[7, 18] - The company plans to launch 5 products in 5 years and have 10+ clinical programs in metabolic health by 2030[19] - Key catalysts include Survodutide Phase 3 obesity data in 2029/2030 and Petrelintide Phase 2 data and Phase 3 initiation[20] Addressing Obesity and Metabolic Health - Over 1 billion people are living with obesity today, requiring a civilization-scale health shift[9] - The GLP-1 revolution has changed expectations, proving obesity is drug treatable and resetting expectations for patients, systems, and markets[10, 11] - By 2030, an estimated 50% of adults globally are expected to live with overweight or obesity[40] - Only ~3% of eligible people in the U S are treated with GLP-1s, and ~12% of Americans have been exposed to GLP-1s[45] Survodutide's Potential - Survodutide, a glucagon/GLP-1 dual agonist, offers coordinated regulation of energy expenditure and energy intake[100] - In a Phase 2 trial, Survodutide dose-dependently reduced body weight by up to 18 7% in 46 weeks[106] - Survodutide also demonstrated breakthrough liver fibrosis improvement in MASH in a Phase 2 trial[128] Petrelintide as a Foundational Therapy - Petrelintide, a long-acting amylin analog, is designed for high-quality, durable weight loss and can be used stand-alone or in combination with CT-388 (GLP-1/GIP)[13] - Petrelintide holds the potential to deliver ~15–20% weight loss with a benign tolerability profile[231] - A Phase 2 trial with Petrelintide/CT-388 is planned for initiation in H1 2026[240]